Tenet On Road to Recovery
Skolnick has a buy recommendation and a two-year price target of $8.70 on Tenet's shares. Her firm makes a market in the company's securities.
Vital Signs Still Weak
To be clear, Tenet still looks like one sick company. By now, critics have offered a long list of problems threatening the company's survival. First and foremost, Tenet carries a huge debt burden -- approaching $4.8 billion -- and generates no positive cash flow. The company's debt-to-capital ratio, hovering in the low 70% range just a few years ago, now stands at an astounding 98%. Tenet needs to boost admissions and lower costs to regain its financial health. Yet even after investing billions of dollars in capital improvements that were intended to attract well-insured patients to its hospitals, the company has seen its volumes steadily erode over the past couple of years. Only uninsured admissions -- which lead to huge bad-debt charges -- have significantly expanded during that timeframe. Florida, once a prized hospital market, has caused exceptional pain. Weak volumes there, caused by fierce competition for a dwindling number of patients who carry insurance, have wiped out gains mustered elsewhere in the system. Tenet has nonetheless clung to Florida as a core holding in its 64-hospital chain. Now, the company must repair that market -- which ranks as its second largest -- to turn around its operations as a whole.- Loading Comments...
- Loading Comments...
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,270.47 | 1,093.48 | 2,167.88 | 34.29 |
Oil *
75.55
|
|
UP
73.00
|
UP
6.24
|
UP
18.86
|
DOWN
0.17
|
10 Yr
3.43%
SPDR Gold
109.74
|
|
+0.72%
|
+0.57%
|
+0.88%
|
-0.49%
|
Data delayed 20 minutes |














